Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Intas
Pharma
Coherus sells Neulasta biosimilar to Intas for up to $558M
Coherus has scored up to $558 million for the last biosimilar in its portfolio, freeing up the company to go all.in on Loqtorzi.
Fraiser Kansteiner
Dec 3, 2024 4:16pm
Accord snags £50M joint investment to boost UK manufacturing
Nov 5, 2024 9:45am
AstraZeneca, BeiGene, Coherus—Fierce Pharma Asia
Dec 1, 2023 8:34am
FDA put Intas plant on import alert, warning letter shows
Nov 29, 2023 1:26pm
AbbVie files patent litigation against generic Rinvoq makers
Nov 22, 2023 9:04am
Novartis-Legend, Astellas, Ajinomoto—Fierce Pharma Asia
Nov 17, 2023 8:00am
